Medtronic Plc NYSE:MDT Price, Chart, News & Insight

NYSE:MDT

Medtronic Sets Final 4.5939 Exchange Ratio for MiniMed Split-Off

Medtronic announced a final exchange ratio of 4.5939 MiniMed shares for each Medtronic share accepted in its previously announced exchange offer, advancing the separation of its diabetes business.

The company is offering up to 225.4 million MiniMed shares in exchange for Medtronic ordinary shares. If the offer is oversubscribed, Medtronic currently intends to distribute its remaining 27.5 million MiniMed shares as well, which would fully separate its ownership interest.

The calculated exchange ratio would have exceeded the permitted maximum, so the final ratio was capped at 4.5939 MiniMed shares per Medtronic share.

If Medtronic distributes all of its remaining MiniMed stake, it expects to accept about 55.0 million Medtronic shares in the exchange. Without the additional distribution, approximately 49.1 million shares would be accepted. Oversubscription would result in proration among participating shareholders.

The exchange offer is scheduled to expire at midnight New York time on October 9, unless extended or terminated.

The transaction represents a major step in Medtronic’s plan to separate MiniMed as an independent publicly traded diabetes technology company, while allowing Medtronic to further concentrate its portfolio on its remaining medical technology businesses.

💬

European Investor 10-08-26

Medtronic Gains Regulatory Clearances for New Cardiac Mapping and Ablation Software

Medtronic announced new regulatory milestones for software used across its cardiac ablation portfolio, including FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software.

The Prism-2 software is designed to support detailed three-dimensional mapping of the heart’s electrical activity during ablation procedures. It uses magnetic and impedance-based tracking to display catheter locations and can support procedures performed with little or no fluoroscopy, potentially reducing reliance on X-ray imaging.

The latest software adds new mapping tools including Beat Matching, Pace Tagging and enhancements to the system’s internal pacing stimulator. These features are intended to help physicians compare heartbeats, identify abnormal electrical signals and improve procedural workflow.

The Affera system is used with Medtronic’s Sphere-9 catheter, which combines high-definition mapping with both pulsed field and radiofrequency ablation.

Medtronic also received CE Mark for its PulseSelect ProxBox Adapter with Proximity Indicator software. The system provides real-time, impedance-based feedback to help physicians determine whether the catheter is close to targeted heart tissue before energy delivery.

The regulatory milestones strengthen Medtronic’s electrophysiology portfolio by expanding software-driven mapping and tissue-proximity capabilities across two of its cardiac ablation platforms.

💬

The Investor 09-30-26

Medtronic Wins FDA Clearance for LigaSure Instrument on Hugo Robotic Surgery System

Medtronic (NYSE: MDT) received FDA clearance for its LigaSure RAS Maryland instrument for use with the Hugo robotic-assisted surgery system, expanding the surgical tools available on the platform in the U.S.

The instrument brings Medtronic’s established LigaSure vessel-sealing technology into robotic surgery. It can seal and cut vessels, tissue and lymphatics up to 7 millimeters in diameter, with vessel sealing taking approximately two seconds. LigaSure technology has been used in more than 45 million procedures across more than 65 countries.

The clearance is also an important step in expanding the capabilities of Medtronic’s Hugo platform as the company competes in the growing robotic-surgery market. Hugo is currently cleared for urologic procedures in the U.S., while Medtronic is working to expand its indications into general and gynecologic surgery. Outside the U.S., Hugo has been used across more than 35 countries and more than 50 types of procedures.

The LigaSure RAS Maryland instrument was previously introduced with Hugo in Europe in 2025 following CE Mark approval.

💬

WS Investor 09-16-26

Medtronic Launches Exchange Offer to Complete MiniMed Separation

Medtronic launched an exchange offer aimed at completing the separation of MiniMed Group, its former diabetes business, allowing Medtronic shareholders to exchange their shares for MiniMed stock.

Medtronic plans to split off at least 80.1% of MiniMed shares through the transaction. MiniMed completed its IPO in March 2026, but Medtronic retained roughly 90% ownership. The exchange is expected to be generally tax-free for Medtronic and participating shareholders for U.S. federal income tax purposes.

Participating shareholders will be offered MiniMed shares at a 7% discount, subject to a maximum exchange ratio of 4.5939 MiniMed shares for each Medtronic share. If the upper limit does not apply, investors are expected to receive approximately $107.53 of MiniMed stock for every $100 of Medtronic shares tendered.

Medtronic currently owns about 252.8 million MiniMed shares and is initially offering up to 225.4 million through the exchange. If demand is high enough, the company intends to offer its remaining 27.5 million shares as well, potentially eliminating its ownership position entirely. If the offer is not fully subscribed, Medtronic plans to divest the remaining stake through another transaction.

The separation would allow Medtronic to concentrate capital on its Cardiovascular, Neuroscience and Surgical businesses, while giving MiniMed greater independence to pursue growth in diabetes technology.

💬

WS Investor 09-14-26

Medtronic Invests $700 Million in Cornerstone Robotics to Expand Surgical Robot Portfolio

Medtronic (NYSE: MDT) announced Tuesday a strategic partnership with Cornerstone Robotics, investing approximately $700 million to expand its presence in the rapidly growing robotic-assisted surgery market.

The agreement gives Medtronic rights to distribute Cornerstone’s Sentire surgical system in select markets outside the U.S. where the platform has regulatory approval. Medtronic plans to offer Sentire alongside its existing Hugo robotic-assisted surgery system, creating a two-platform portfolio aimed at different clinical, operational and economic requirements.

Sentire received CE Mark in May 2026 for minimally invasive general, gynecologic, thoracic and urologic procedures and is also approved in China and Singapore. The system features an immersive console and dual-console capability.

The investment strengthens one of Medtronic’s key long-term growth opportunities. Global penetration of robotic-assisted surgery remains in the single digits, leaving substantial room for hospitals to transition from conventional procedures toward robotic systems.

Medtronic also highlighted accelerating adoption of Hugo, which is now used in more than 35 countries across six continents and received U.S. FDA clearance within the past year. Hugo procedure volumes are currently growing at more than twice the overall robotic surgery market rate, with cumulative procedures expected to exceed 50,000 globally by the end of Medtronic’s fiscal year.

The Cornerstone partnership gives Medtronic a broader offering as it competes in a surgical robotics market dominated by Intuitive Surgical. Combined with continued investment in Hugo, AI, digital surgery, integrated stapling and new instruments, the Sentire deal could strengthen Medtronic’s ability to capture a larger share of the expanding global robotic surgery market.

💬

WS Investor 09-01-26

Medtronic Stock Rises 1.5% After Strong Q1 Results and Raised FY2027 Guidance

Medtronic (NYSE: MDT) shares rose about 1.5% after the medical-device company reported strong fiscal first-quarter results and raised its full-year revenue and earnings outlook.

Revenue reached $9.76 billion, increasing 13.7% both reported and organically and coming roughly 200 basis points above the midpoint of the company’s guidance. Adjusted EPS rose 15.1% to $1.45, also ahead of Medtronic’s expectations. The quarter benefited from an extra fiscal week, which contributed approximately $570 million to revenue.

Growth was broad-based across Medtronic’s portfolio. Cardiovascular revenue increased 18.9% organically, including 88% growth in Cardiac Ablation Solutions, while Neuroscience grew 9.3%. Medical Surgical increased 10.2%, and the Diabetes business delivered 14.9% organic growth.

Profitability also improved. GAAP operating profit increased 22.1% to $1.76 billion, while GAAP net income jumped 41.4% to $1.47 billion. Adjusted operating profit rose 14.9% to $2.32 billion.

The likely key driver behind the positive stock reaction was Medtronic’s stronger outlook. The company raised its FY2027 organic revenue growth forecast to 7.25%-7.75% from 6.75%-7.25% and increased the lower end of its adjusted EPS guidance, with the new range at $5.94-$6.00 compared with $5.90-$6.00 previously.

Medtronic’s results also highlight strength in several faster-growing medical technology markets, particularly cardiac ablation, diabetes technology and robotic-assisted surgery. Continued growth from these newer platforms alongside the company’s established cardiovascular and neuroscience franchises could support a stronger long-term growth profile.

💬

WS Investor 09-01-26

# Medtronic Expands European Approval for Affera System to Treat Ventricular Arrhythmias

Medtronic (NYSE: MDT) announced an expanded CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 Catheter, allowing the technology to be used in Europe to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes.

The expanded indication opens another potential growth market for Medtronic's cardiac ablation business as the company continues the global rollout of its Sphere-9 technology.

## Sphere-9 Gains First-of-Its-Kind CE Mark

According to Medtronic, Sphere-9 is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter to receive CE Mark authorization for ventricular ablation.

The system combines high-definition cardiac mapping with both pulsed field and radiofrequency ablation in a single catheter. This allows physicians to map abnormal electrical activity and select between the two energy sources during cardiac ablation procedures.

Medtronic said the technology could address an important unmet need in ventricular arrhythmias, where treatment options include medications, implanted defibrillators and catheter ablation.

## U.S. Clinical Trial Underway

Medtronic is also working toward expanding Sphere-9's ventricular indication in the United States.

The FDA has granted the catheter Breakthrough Device Designation for treating ventricular arrhythmias, providing an expedited regulatory pathway for the technology.

Enrollment is now underway in the Sphere VT pivotal trial, which will evaluate Sphere-9 for ventricular tachycardia and is intended to support a potential future U.S. approval.

The expanded European indication adds to Medtronic's broader push into next-generation electrophysiology. For the company, extending Sphere-9 beyond its existing applications could expand the addressable market for the Affera platform while strengthening its position in the growing cardiac ablation market.

💬

Global Finance News 08-07-26

Medtronic (MDT) rose about 5% after delivering a strong earnings report that exceeded expectations, posted its fastest annual revenue growth in a decade, and issued better-than-expected fiscal 2027 guidance.

The medical device giant reported fourth-quarter revenue of $9.8 billion, up 9.9% year-over-year, while non-GAAP EPS came in at $1.55, ahead of management's guidance. The company benefited from broad-based strength across its portfolio, particularly in cardiovascular devices, diabetes care, and surgical products. One standout was Cardiac Ablation Solutions, where revenue surged 78% globally and 124% in the United States as Medtronic continued gaining market share.

Investors were particularly encouraged by the company's outlook. Medtronic expects fiscal 2027 organic revenue growth of 6.75% to 7.25% and non-GAAP EPS of $5.90 to $6.00, implying earnings growth of roughly 7% to 9%. The guidance suggests management expects its growth momentum to continue despite tariffs and other macroeconomic headwinds.

The company also highlighted several growth drivers, including its Affera cardiac ablation platform, Hugo robotic surgery system, Symplicity renal denervation technology, and Stealth AXiS surgical navigation platform. Recent acquisitions and investments in areas such as coronary intervention, neurovascular devices, neuromodulation, and cardiovascular technologies further reinforced confidence in future growth prospects.

Another positive factor for income-focused investors was Medtronic's announcement of its 49th consecutive annual dividend increase, raising the annual dividend to $2.88 per share. The company generated $7.3 billion of operating cash flow during fiscal 2026 and ended the year with $9.2 billion in cash and investments, highlighting its strong financial position.

Overall, investors appear to be rewarding Medtronic for delivering accelerating revenue growth, strong execution in key product categories, a healthy pipeline of new technologies, and an upbeat outlook for fiscal 2027. The combination of earnings upside, guidance growth, market-share gains, and dividend increases explains the stock's strong move higher following the results.

💬

Global Finance News 06-03-26

Medtronic plc announced it has received CE Mark approval for its Stealth AXiS surgical system, a next-generation platform integrating planning, navigation, and robotics into a single solution.

The system is designed for spine and cranial procedures and features AI-driven capabilities, including real-time anatomical tracking and advanced visualization tools to support more precise and personalized surgeries. The platform also connects pre-, intra-, and post-operative workflows within Medtronic’s broader digital ecosystem.

The approval follows recent U.S. FDA clearances, enabling the company to expand access to the technology across Europe.

Source: Medtronic press release, PRNewswire

💬

The Investor 04-28-26

Medtronic reported positive clinical progress for its Affera™ cardiac ablation technologies, highlighting new data and regulatory milestones at the Heart Rhythm Society 2026 meeting. Interim results showed that 65.5% of patients treated with the Sphere-9™ catheter remained free from ventricular tachycardia recurrence after six months.

The Sphere-9 catheter also received FDA Breakthrough Device Designation for treating ventricular tachycardia, while a U.S. pivotal trial has been approved. Additional data for the Sphere-360™ catheter demonstrated high durability in atrial fibrillation procedures, with consistent outcomes across different patient anatomies.

Medtronic also announced the launch of a new global study to evaluate the technology in a broader group of atrial fibrillation patients, supporting continued expansion and clinical validation of its cardiac rhythm treatment portfolio.
PRNewswire

💬

The Investor 04-26-26

12-30-25WS News

NYSE:MDTFollow

NYSE:MDT